122 related articles for article (PubMed ID: 37248927)
1. Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies.
van den Heuvel M; Holdenrieder S; Schuurbiers M; Cigoianu D; Trulson I; van Rossum H; Lang D
Tumour Biol; 2024; 46(s1):S233-S268. PubMed ID: 37248927
[TBL] [Abstract][Full Text] [Related]
2. Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.
Chen Z; Liu L; Zhu F; Cai X; Zhao Y; Liang P; Ou L; Zhong R; Yu Z; Li C; Li J; Xiong S; Feng Y; Cheng B; Liang H; Xie Z; Liang W; He J
Cancer Med; 2022 Aug; 11(16):3115-3125. PubMed ID: 35543090
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
4. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
[TBL] [Abstract][Full Text] [Related]
5. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
6. Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study.
Huang J; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Li X; Liu G; Hu H; Huang S; Yang X
BMC Cancer; 2023 Aug; 23(1):812. PubMed ID: 37649021
[TBL] [Abstract][Full Text] [Related]
7. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
Zhao T; Mao G; Chen M
Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
Trulson I; Holdenrieder S
Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
[TBL] [Abstract][Full Text] [Related]
9. Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.
Yang X; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Hu H; Huang J; Huang S
Ther Adv Med Oncol; 2023; 15():17588359231206282. PubMed ID: 37920256
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
[TBL] [Abstract][Full Text] [Related]
11. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
Bi H; Yin L; Fang W; Song S; Wu S; Shen J
Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
[TBL] [Abstract][Full Text] [Related]
12. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
13. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
14. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
15. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
16. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
Zhang ZH; Han YW; Liang H; Wang LM
Cancer Med; 2015 Nov; 4(11):1633-8. PubMed ID: 26333429
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].
Gao J; Zhang L; Peng K; Sun H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):886-891. PubMed ID: 35790439
[TBL] [Abstract][Full Text] [Related]
20. [Effects of chemotherapy combined with Chinese herbal medicine Kangliu Zengxiao decoction on tumor markers of patients with advanced non-small-cell lung cancer: a randomized, controlled trial].
Yan GY; Xu ZY; Deng HB; Wan ZY; Zhang L; Zhu JY
Zhong Xi Yi Jie He Xue Bao; 2011 May; 9(5):525-30. PubMed ID: 21565138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]